The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
H. J. Deeg
No relevant relationships to disclose
O. Odenike
No relevant relationships to disclose
B. L. Scott
No relevant relationships to disclose
Z. Estrov
No relevant relationships to disclose
J. E. Cortes
No relevant relationships to disclose
D. A. Thomas
No relevant relationships to disclose
H. J. Zhu
Employment or Leadership Position - S*Bio
Stock Ownership - S*Bio
H. Kantarjian
No relevant relationships to disclose
S. Verstovsek
No relevant relationships to disclose